Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiloride for Lithium-Induced NDI
NCT05044611Phase 4Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in nephrogenic diabetes insipidus (NDI) comparing Amiloride with Placebo (2 arms). Primary endpoint: Urine concentration defect at 2 months. Started Jan 2023; status: active, not recruiting.
02
Drugs
amiloride
03
Conditions
nephrogenic diabetes insipidus (NDI)
Beyond the preview
Go deeper on NCT05044611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05044611.